Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the interest coverage ratio high or low?
The interest coverage ratio of -54.05x is 67% below its 5-year average of -32.34x, near the low end of its 5-year range (-67.80x–-11.26x).
As of the fiscal period ended Tuesday, December 31, 2019. 0.03% below its 12-month average of -54.03x.
Reported quarterly interest coverage; no daily interpolation. Q4 FY2019 (2019-12-31): -54.05x.
INTEREST COVERAGE RATIO
-54.05x
INTEREST COVERAGE RATIO AVG TTM
-54.03x
INTEREST COVERAGE RATIO AVG 3Y
-42.48x
INTEREST COVERAGE RATIO AVG 5Y
-32.34x
INTEREST COVERAGE RATIO AVG 10Y
N/A
INTEREST COVERAGE RATIO AVG 15Y
N/A
INTEREST COVERAGE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-0.03%
CURRENT VS 3Y AVG
-27.23%
CURRENT VS 5Y AVG
-67.12%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-6.38x
median of 528 covered companies
CURRENT VS SECTOR MEDIAN
-747.82%
vs the sector median at left
Fate Therapeutics, Inc.
Market Cap
$271.00M
Interest Coverage Ratio
-54.05x
TTM Avg
-54.03x
3Y Avg
-42.48x
5Y Avg
-32.34x
Market Cap
$271.35M
Interest Coverage Ratio
-120.84x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$270.31M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$270.23M
Interest Coverage Ratio
-203.41x
TTM Avg
43.82x
3Y Avg
43.82x
5Y Avg
43.82x
Market Cap
$272.78M
Interest Coverage Ratio
-4.86x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$273.07M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$267.93M
Interest Coverage Ratio
-10.18x
TTM Avg
0.19x
3Y Avg
0.19x
5Y Avg
0.19x
Market Cap
$264.94M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$264.74M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | INTEREST COVERAGE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fate Therapeutics, Inc. (FATE) | $271.00M | -54.05x | -54.03x | -42.48x | -32.34x |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $271.35M | -120.84x | N/A | N/A | N/A |
| Vanda Pharmaceuticals Inc. (VNDA)vs › | $270.31M | N/A | N/A | N/A | N/A |
| SAB Biotherapeutics, Inc. (SABS)vs › | $270.23M | -203.41x | 43.82x | 43.82x | 43.82x |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $272.78M | -4.86x | N/A | N/A | N/A |
| Scribe Therapeutics Inc. (SCTX)vs › | $273.07M | N/A | N/A | N/A | N/A |
| Treace Medical Concepts, Inc. (TMCI)vs › | $267.93M | -10.18x | 0.19x | 0.19x | 0.19x |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $264.94M | N/A | N/A | N/A | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $264.74M | N/A | N/A | N/A | N/A |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $262.81M | N/A | N/A | N/A | N/A |
Interest Coverage
-54.0x
Debt/Equity
0.49
Current Ratio
4.85
Formula: Interest Coverage = EBIT / Interest Expense
Reference ranges:
Note: Interest coverage should be compared with historical interest expense, operating income, and industry capital structure.
Interest Coverage = EBIT / Interest Expense
The interest coverage ratio measures operating earnings relative to interest expense.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | INTEREST COVERAGE RATIO |
|---|---|
| 2019-12-31 | -54.05x |
| 2019-09-30 | -67.80x |
| 2019-06-30 | -58.89x |
| 2019-03-31 | -50.48x |
| 2018-12-31 | -38.93x |
| 2018-09-30 | -38.91x |
| 2018-06-30 | -46.13x |
| 2018-03-31 | -34.11x |
| 2017-12-31 | -29.72x |
| 2017-09-30 | -27.35x |
| 2017-06-30 | -45.14x |
| 2017-03-31 | -37.48x |
| 2016-12-31 | -23.26x |
| 2016-09-30 | -21.79x |
| 2016-06-30 | -18.40x |
| 2016-03-31 | -16.22x |
| 2015-12-31 | -12.87x |
| 2015-09-30 | -11.26x |
| 2015-06-30 | -12.82x |
| 2015-03-31 | -13.13x |
| 2014-12-31 | -20.42x |
| 2014-09-30 | -32.00x |
| 2014-06-30 | -215.71x |
| 2014-03-31 | -161.33x |
| 2013-09-30 | -22.58x |
| 2013-06-30 | -48.51x |
| 2013-03-31 | -33.56x |
